

## DENMARK

### Recent and planned developments in pharmaceutical policies 2023

#### CHANGES IN PRICING

The current voluntary price cap agreement between the Danish Ministry of the Interior and Health, the Danish Regions, and the Danish Association of the Pharmaceutical Industry ends on March 31st 2023.

In August 2022 Amgros, the centralized procurements organization in Denmark, prepared a list of different 13 models for alternative prices agreements (including models for alternative prices agreements) - <https://amgros.dk/media/3598/oversigt-over-alternative-aftalemodeller-amgros-2022.pdf>. The list contains suggestions for suppliers to help them prepare for their dialogue with Amgros.

#### CHANGES IN REIMBURSEMENT

A new 4-year **pilot scheme on risk sharing** for primary care products has been launched on June 1<sup>st</sup> 2022. The pilot scheme is open for applications until May 31<sup>st</sup> 2024.

The DKMA is currently reassessing reimbursement for **non-insulins, opioids, and eye and ear medicines** (ATC S01, S02, and S03).

#### OTHER CHANGES

We have had election for Government in November 2022, which has resulted in a merge of the Ministry of the Interior and the Ministry of Health; now **the Danish Ministry of the Interior and Health**.

#### SPECIAL TOPIC:

#### Developing and implementing pharmaceutical policies in view of the current challenges (soaring inflation, medicine price increases, increasing no. of medicine shortages)

##### Medicines shortages

To mitigate the potential shortages of **critical antibiotics** in the primary care sector, the DKMA has changed practice regarding requirements for delivery capacities temporarily. This change will help secure smaller available volumes of critical antibiotics (ATC J01). In Denmark, the supply of these critical antibiotics has been stable.

The DKMA has encouraged the pharmacies to return morphine 10 mg packages to the wholesaler, if they have more in stock than what is normally sold in 3 weeks. This encouragement is due to a **current serious shortage** on morphine 10 mg and an unevenly distributed stock of available packs at the Danish retail pharmacies.

In 2023, the **safety stock** for hospitals medicines will transition to a more strategic stock. We will stock medicines where we are expecting to have supply difficulties. The stock levels will also become more dynamic in order to adjust stock targets according to the supply situation.

##### Price increases

The government has entered into an **agreement on inflation aid** that (among many other things) reduces the thresholds for the patients' out-of-pocket payments for reimbursable medicines. The new thresholds will be valid for the remaining of 2023. It is expected that the agreement will affect approximately 2,200 children and 200,000 adults.